Deven Choksey recommended Accumulate rating on Divis Laboratories with a target price of Rs 6795 in its research report dated ...

Stay updated with the Divis Labs Stock Liveblog, your one-stop destination for real-time information and analysis of a ...

Join us on the Divis Labs Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock.

The Hyderabad-based pharmaceutical company's consolidated revenue from operations grew 16 per cent YoY to Rs 2,715 crore in ...

The Hyderabad-based pharma company is set to stage a strong financial performance for the July-September period. Here's what analysts expect to see in the drug maker's upcoming earnings report.

ICICI Securities is bearish on Divis Laboratories has recommended sell rating on the stock with a target price of Rs 5400 in its research report dated 09, 2025.

Earnings call Divi's Laboratories posted a 25.4% YoY revenue growth for Q3 FY25, with PAT rising 64.5% YoY. Custom synthesis continues to drive growth, while backward integration via the new Kakinada ...

Hyderabad: Divi's Laboratories registered a 35% jump in consolidated net profit for the second quarter ended September 30, ...

Divi's Laboratories recorded a decent set of numbers for the September quarter, with both profit and revenue rising ...

Stock market today: Indian stock markets initially opened lower but then bounced back, trading flat at the time of this report on Wednesday following India’s anti ...

Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q2 2026 earnings on Nov 7, 2025. The consensus estimate for Q2 2026 revenue is $25.86 billion, and the earnings are expected to come in at ...

Divis Laboratories Ltd has informed BSE that it has had a successful inspection by the US-FDA from 16th to 20th June, 2014, without any observations, for its Unit-I at vill. Lingojigudem, Choutuppal ...